Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

45 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 18.8M shares of 55.6M outstanding shares and own 33.8% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.81M shares), Atlas Venture Life Science Advisors, LLC (2.76M shares), FMR LLC (2.59M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.08M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), RiverVest Venture Management LLC (1.44M shares), Rock Springs Capital Management LP (1.19M shares), AJU IB Investment Co., Ltd. (668K shares), Soleus Capital Management, L.P. (477K shares), and Artal Group S.A. (450K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.